Allergy Asthma Immunol Res.  2014 Jan;6(1):13-21. 10.4168/aair.2014.6.1.13.

Molecular Genetic Mechanisms of Chronic Urticaria

Affiliations
  • 1Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea. hspark@ajou.ac.kr

Abstract

Chronic urticaria (CU) is a common allergic skin disease that requires long-term pharmacological treatment. Some patients with severe CU suffer a poor quality of life. Although the pathogenic mechanisms of CU are not clearly understood, several groups have suggested that genetic mechanisms are involved in various CU cohorts. To further understand the molecular genetic mechanisms of CU, we summarize recent genetic data in this review. Although a few HLA alleles were suggested to be candidate markers in different ethnic groups, further replication studies that apply the recent classification are needed. Genetic polymorphisms in histamine-related genes, including FcepsilonRI and HNMT, were suggested to be involved in mast cell activation and histamine metabolism. Several genetic polymorphisms of leukotriene-related genes, such as ALOX5, LTC4S, and the PGE2 receptor gene PTGER4, were suggested to be involved in leukotriene overproduction, a pathogenic mechanism. Further investigations using candidate gene approaches and genome-wide association studies (GWAS) will provide new insights into the molecular genetic mechanisms of CU, which will provide new marker genes for differentiation of CU phenotypes and identification of potential therapeutic targets.

Keyword

Chronic urticaria; genetic association; leukotriene; mast cell

MeSH Terms

Alleles
Classification
Cohort Studies
Dinoprostone
Ethnic Groups
Genome-Wide Association Study
Histamine
Humans
Leukotriene C4
Mast Cells
Metabolism
Molecular Biology*
Phenotype
Polymorphism, Genetic
Quality of Life
Skin Diseases
Urticaria*
Dinoprostone
Histamine
Leukotriene C4

Cited by  1 articles

KAAACI Standardization Committee Report on the procedures and applications of the diagnostic tests for drug allergy
Min-Suk Yang, Ga-Young Ban, Min-Hye Kim, Kyung-Hwan Lim, Hyouk-Soo Kwon, Woo-Jung Song, Jae-Woo Jung, Jeongmin Lee, Dong In Suh, Jae-Woo Kwon, Sae-Hoon Kim, Yoo Seob Shin, Hye-Ryun Kang, Tae-Bum Kim, Byung-Jae Lee, Ai-Young Lee, Hae-Sim Park, Sang-Heon Cho
Allergy Asthma Respir Dis. 2017;5(5):239-247.    doi: 10.4168/aard.2017.5.5.239.


Reference

1. Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, Canonica GW, Church MK, Godse KV, Grattan CE, Greaves MW, Hide M, Kalogeromitros D, Kaplan AP, Saini SS, Zhu XJ, Zuberbier T. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy. 2011; 66:317–330.
2. Greaves MW. Chronic urticaria. N Engl J Med. 1995; 332:1767–1772.
3. Kaplan AP. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res. 2012; 4:326–331.
4. Asero R. Chronic idiopathic urticaria: a family study. Ann Allergy Asthma Immunol. 2002; 89:195–196.
5. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau A, Grattan CE, Kapp A, Merk HF, Rogala B, Saini S, Sánchez-Borges M, Schmid-Grendelmeier P, Schünemann H, Staubach P, Vena GA, Wedi B, Maurer M. Global Allergy and Asthma European Network. European Dermatology Forum. World Allergy Organization. EAACI/ GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009; 64:1417–1426.
6. Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol. 2004; 114:465–474.
7. Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol. 2012; 129:1307–1313.
8. Najib U, Bajwa ZH, Ostro MG, Sheikh J. A retrospective review of clinical presentation, thyroid autoimmunity, laboratory characteristics, and therapies used in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2009; 103:496–501.
9. Gaig P, Olona M, Muñoz Lejarazu D, Caballero MT, Domínguez FJ, Echechipia S, García Abujeta JL, Gonzalo MA, Lleonart R, Martínez Cócera C, Rodríguez A, Ferrer M. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol. 2004; 14:214–220.
10. Staubach P, Dechene M, Metz M, Magerl M, Siebenhaar F, Weller K, Zezula P, Eckhardt-Henn A, Maurer M. High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria. Acta Derm Venereol. 2011; 91:557–561.
11. Chung MC, Symons C, Gilliam J, Kaminski ER. Stress, psychiatric co-morbidity and coping in patients with chronic idiopathic urticaria. Psychol Health. 2010; 25:477–490.
12. Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, Bousquet P, Celik G, Demoly P, Gomes ER, Niżankowska-Mogilnicka E, Romano A, Sanchez-Borges M, Sanz M, Torres MJ, De Weck A, Szczeklik A, Brockow K. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy. 2011; 66:818–829.
13. Zuberbier T, Chantraine-Hess S, Hartmann K, Czarnetzki BM. Pseudoallergen-free diet in the treatment of chronic urticaria. A prospective study. Acta Derm Venereol. 1995; 75:484–487.
14. Doña I, Blanca-López N, Cornejo-García JA, Torres MJ, Laguna JJ, Fernández J, Rosado A, Rondón C, Campo P, Agúndez JA, Blanca M, Canto G. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy. 2011; 41:86–95.
15. Gómez E, Torres MJ, Mayorga C, Blanca M. Immunologic evaluation of drug allergy. Allergy Asthma Immunol Res. 2012; 4:251–263.
16. Sánchez-Borges M. NSAID hypersensitivity (respiratory, cutaneous, and generalized anaphylactic symptoms). Med Clin North Am. 2010; 94:853–864.
17. Erbagci Z. Multiple NSAID intolerance in chronic idiopathic urticaria is correlated with delayed, pronounced and prolonged autoreactivity. J Dermatol. 2004; 31:376–382.
18. Kim SH, Park HS. Genetic markers for differentiating aspirin-hypersensitivity. Yonsei Med J. 2006; 47:15–21.
19. Ye YM, Kim JE, Nahm DI, Kim SH, Suh CH, Nahm DH, Park HS. Comparison of clinical characteristics and prognosis of chronic urticaria according to the aspirin sensitivity. Korean J Asthma Allergy Clin Immunol. 2005; 25:194–199.
20. Palikhe NS, Sin HJ, Kim SH, Sin HJ, Hwang EK, Ye YM, Park HS. Genetic variability of prostaglandin E2 receptor subtype EP4 gene in aspirin-intolerant chronic urticaria. J Hum Genet. 2012; 57:494–499.
21. Choi SJ, Ye YM, Hur GY, Shin SY, Han JH, Park HS. Neutrophil activation in patients with ASA-induced urticaria. J Clin Immunol. 2008; 28:244–249.
22. Kim JE, Lee JW, Sung JM, Kim JH, Choi GS, Ye YM, Nahm DH, Park HS. Comparison of clinical characteristics between acute and chronic acetylsalicylic acid-intolerant urticaria. Korean J Asthma Allergy Clin Immunol. 2010; 30:93–99.
23. Luquin E, Kaplan AP, Ferrer M. Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-respon siveness to other stimuli. Clin Exp Allergy. 2005; 35:456–460.
24. Nam YH, Kim JH, Jin HJ, Hwang EK, Shin YS, Ye YM, Park HS. Effects of omalizumab treatment in patients with refractory chronic urticaria. Allergy Asthma Immunol Res. 2012; 4:357–361.
25. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993; 328:1599–1604.
26. Niimi N, Francis DM, Kermani F, O'Donnell BF, Hide M, Kobza-Black A, Winkelmann RK, Greaves MW, Barr RM. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol. 1996; 106:1001–1006.
27. Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Ruëff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011; 128:202–209.e5.
28. Kim MA, Park HS. Highly cytokinergic IgE antibodies and autoimmune mechanisms. Allergy Asthma Immunol Res. 2012; 4:311–312.
29. Ferrer M, Luquin E, Sanchez-Ibarrola A, Moreno C, Sanz ML, Kaplan AP. Secretion of cytokines, histamine and leukotrienes in chronic urticaria. Int Arch Allergy Immunol. 2002; 129:254–260.
30. Hennino A, Bérard F, Guillot I, Saad N, Rozières A, Nicolas JF. Pathophysiology of urticaria. Clin Rev Allergy Immunol. 2006; 30:3–11.
31. Kraft S, Rana S, Jouvin MH, Kinet JP. The role of the FcepsilonRI beta-chain in allergic diseases. Int Arch Allergy Immunol. 2004; 135:62–72.
32. Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol. 2007; 7:365–378.
33. Bae JS, Kim SH, Ye YM, Yoon HJ, Suh CH, Nahm DH, Park HS. Significant association of FcepsilonRIalpha promoter polymorphisms with aspirin-intolerant chronic urticaria. J Allergy Clin Immunol. 2007; 119:449–456.
34. Palikhe N, Kim SH, Yang EM, Kang YM, Ye YM, Hur GY, Park HS. Analysis of high-affinity IgE receptor (FcepsilonR1) polymorphisms in patients with aspirin-intolerant chronic urticaria. Allergy Asthma Proc. 2008; 29:250–257.
35. Yamauchi K, Sekizawa K, Suzuki H, Nakazawa H, Ohkawara Y, Katayose D, Ohtsu H, Tamura G, Shibahara S, Takemura M, Maeyama K, Watanabe T, Sasaki H, Shirato K, Takishima T. Structure and function of human histamine N-methyltransferase: critical enzyme in histamine metabolism in airway. Am J Physiol. 1994; 267:L342–L349.
36. Fukui K, Miyake Y. Molecular cloning and chromosomal localization of a human gene encoding D-amino-acid oxidase. J Biol Chem. 1992; 267:18631–18638.
37. Kim SH, Kang YM, Kim SH, Cho BY, Ye YM, Hur GY, Park HS. Histamine N-methyltransferase 939A>G polymorphism affects mRNA stability in patients with acetylsalicylic acid-intolerant chronic urticaria. Allergy. 2009; 64:213–221.
38. Choi JH, Kim SH, Suh CH, Nahm DH, Park HS. Polymorphisms of high-affinity IgE receptor and histamine-related genes in patients with ASA-induced urticaria/angioedema. J Korean Med Sci. 2005; 20:367–372.
39. Piconi S, Trabattoni D, Iemoli E, Fusi ML, Villa ML, Milazzo F, Clerici M. Immune profiles of patients with chronic idiopathic urticaria. Int Arch Allergy Immunol. 2002; 128:59–66.
40. Walsh LJ, Trinchieri G, Waldorf HA, Whitaker D, Murphy GF. Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci U S A. 1991; 88:4220–4224.
41. Carroll MC, Katzman P, Alicot EM, Koller BH, Geraghty DE, Orr HT, Strominger JL, Spies T. Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes. Proc Natl Acad Sci U S A. 1987; 84:8535–8539.
42. Choi JH, Kim SH, Cho BY, Lee SK, Kim SH, Suh CH, Park HS. Association of TNF-alpha promoter polymorphisms with aspirin-induced urticaria. J Clin Pharm Ther. 2009; 34:231–238.
43. Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, Itoh K. Polymorphism of the 5'-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens. 1998; 51:605–612.
44. Redington AE, Roche WR, Holgate ST, Howarth PH. Co-localization of immunoreactive transforming growth factor-beta 1 and decorin in bronchial biopsies from asthmatic and normal subjects. J Pathol. 1998; 186:410–415.
45. Gomez G, Ramirez CD, Rivera J, Patel M, Norozian F, Wright HV, Kashyap MV, Barnstein BO, Fischer-Stenger K, Schwartz LB, Kepley CL, Ryan JJ. TGF-beta 1 inhibits mast cell Fc epsilon RI expression. J Immunol. 2005; 174:5987–5993.
46. Bissonnette EY, Enciso JA, Befus AD. TGF-beta1 inhibits the release of histamine and tumor necrosis factor-alpha from mast cells through an autocrine pathway. Am J Respir Cell Mol Biol. 1997; 16:275–282.
47. Hosseini Farahabadi S, Tavakkol-Afshari J, Ganjali R, Rafatpanah H, Ghaffari J, Farid-Hosseini R. Association between the polymorphism of TGF-beta1 gene promoter (-509C>T) and idiopathic chronic urticaria. Iran J Allergy Asthma Immunol. 2006; 5:109–113.
48. Park HJ, Ye YM, Hur GY, Kim SH, Park HS. Association between a TGFbeta1 promoter polymorphism and the phenotype of aspirin-intolerant chronic urticaria in a Korean population. J Clin Pharm Ther. 2008; 33:691–697.
49. Kim SH, Park HS, Holloway JW, Shin HD, Park CS. Association between a TGFbeta1 promoter polymorphism and rhinosinusitis in aspirin-intolerant asthmatic patients. Respir Med. 2007; 101:490–495.
50. Silverman ES, Palmer LJ, Subramaniam V, Hallock A, Mathew S, Vallone J, Faffe DS, Shikanai T, Raby BA, Weiss ST, Shore SA. Transforming growth factor-beta1 promoter polymorphism C-509T is associated with asthma. Am J Respir Crit Care Med. 2004; 169:214–219.
51. Marquardt DL, Gruber HE, Wasserman SI. Adenosine release from stimulated mast cells. Proc Natl Acad Sci U S A. 1984; 81:6192–6196.
52. Ramkumar V, Stiles GL, Beaven MA, Ali H. The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem. 1993; 268:16887–16890.
53. Reeves JJ, Jones CA, Sheehan MJ, Vardey CJ, Whelan CJ. Adenosine A3 receptors promote degranulation of rat mast cells both in vitro and in vivo. Inflamm Res. 1997; 46:180–184.
54. Kim SH, Nam EJ, Kim YK, Ye YM, Park HS. Functional variability of the adenosine A3 receptor (ADORA3) gene polymorphism in aspirin-induced urticaria. Br J Dermatol. 2010; 163:977–985.
55. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011; 29:71–109.
56. O'Garra A, Vieira P. T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol. 2007; 7:425–428.
57. Maynard CL, Weaver CT. Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol Rev. 2008; 226:219–233.
58. Salim PH, Jobim M, Bredemeier M, Chies JA, Brenol JC, Jobim LF, Xavier RM. Interleukin-10 gene promoter and NFKB1 promoter insertion/deletion polymorphisms in systemic sclerosis. Scand J Immunol. 2013; 77:162–168.
59. Salhi A, Rodrigues V Jr, Santoro F, Dessein H, Romano A, Castellano LR, Sertorio M, Rafati S, Chevillard C, Prata A, Alcaïs A, Argiro L, Dessein A. Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J Immunol. 2008; 180:6139–6148.
60. Ates O, Müsellim B, Ongen G, Topal-Sarikaya A. Association between 'interleukin' 10 gene (IL10) polymorphisms and systemic sclerosis with interstitial lung involvement. Rheumatol Int. 2008; 28:1123–1126.
61. Beretta L, Cappiello F, Barili M, Scorza R. Proximal interleukin-10 gene polymorphisms in Italian patients with systemic sclerosis. Tissue Antigens. 2007; 69:305–312.
62. Palikhe NS, Kim SH, Jin HJ, Nam YH, Park HS. Association of interleukin 10 promoter polymorphism at -819 T>C with aspirin-induced urticaria in a Korean population. Ann Allergy Asthma Immunol. 2011; 107:544–546.
63. Kennedy Norton S, Barnstein B, Brenzovich J, Bailey DP, Kashyap M, Speiran K, Ford J, Conrad D, Watowich S, Moralle MR, Kepley CL, Murray PJ, Ryan JJ. IL-10 suppresses mast cell IgE receptor expression and signaling in vitro and in vivo. J Immunol. 2008; 180:2848–2854.
64. Grimbaldeston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ. Mast cell-derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat Immunol. 2007; 8:1095–1104.
65. Setkowicz M, Mastalerz L, Podolec-Rubis M, Sanak M, Szczeklik A. Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years. J Allergy Clin Immunol. 2009; 123:174–178.
66. Narayanankutty A, Reséndiz-Hernández JM, Falfán-Valencia R, Teran LM. Biochemical pathogenesis of aspirin exacerbated respiratory disease (AERD). Clin Biochem. 2013; 46:566–578.
67. Celik G, Bavbek S, Misirligil Z, Melli M. Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E(2) on this release from peripheral blood leucocytes in aspirin-induced asthmatic patients. Clin Exp Allergy. 2001; 31:1615–1622.
68. Feng C, Beller EM, Bagga S, Boyce JA. Human mast cells express multiple EP receptors for prostaglandin E2 that differentially modulate activation responses. Blood. 2006; 107:3243–3250.
69. Cornejo-García JA, Jagemann LR, Blanca-López N, Doña I, Flores C, Guéant-Rodríguez RM, Torres MJ, Fernández J, Laguna JJ, Rosado A, Agúndez JA, García-Martín E, Canto G, Guéant JL, Blanca M. Genetic variants of the arachidonic acid pathway in non-steroidal anti-inflammatory drug-induced acute urticaria. Clin Exp Allergy. 2012; 42:1772–1781.
70. Kim SH, Choi JH, Holloway JW, Suh CH, Nahm DH, Ha EH, Park CS, Park HS. Leukotriene-related gene polymorphisms in patients with aspirin-intolerant urticaria and aspirin-intolerant asthma: differing contributions of ALOX5 polymorphism in Korean population. J Korean Med Sci. 2005; 20:926–931.
71. Kim SH, Yang EM, Park HJ, Ye YM, Lee HY, Park HS. Differential contribution of the CysLTR1 gene in patients with aspirin hypersensitivity. J Clin Immunol. 2007; 27:613–619.
72. Mastalerz L, Setkowicz M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol. 2004; 113:771–775.
73. Sánchez-Borges M, Acevedo N, Vergara C, Jiménez S, Zabner-Oziel P, Monzón A, Caraballo L. The A-444C polymorphism in the leukotriene C4 synthase gene is associated with aspirin-induced urticaria. J Investig Allergol Clin Immunol. 2009; 19:375–382.
74. Mastalerz L, Setkowicz M, Sanak M, Rybarczyk H, Szczeklik A. Familial aggregation of aspirin-induced urticaria and leukotriene C synthase allelic variant. Br J Dermatol. 2006; 154:256–260.
75. Torres-Galván MJ, Ortega N, Sánchez-García F, Blanco C, Carrillo T, Quiralte J. LTC4-synthase A-444C polymorphism: lack of association with NSAID-induced isolated periorbital angioedema in a Spanish population. Ann Allergy Asthma Immunol. 2001; 87:506–510.
76. Aydogan K, Karadogan SK, Akdag I, Tunali S. HLA class I and class II antigens in Turkish patients with chronic ordinary urticaria. Clin Exp Dermatol. 2006; 31:424–429.
77. Bozek A, Krajewska J, Filipowska B, Polanska J, Rachowska R, Grzanka A, Jarzab J. HLA status in patients with chronic spontaneous urticaria. Int Arch Allergy Immunol. 2010; 153:419–423.
78. Calamita Z, Bronhara Pelá Calamita A. HLA in patients with chronic spontaneous urticaria who are positive for anti-thyroid antibodies. J Eur Acad Dermatol Venereol. 2013; 27:661–662.
79. Coban M, Erdem T, Ozdemir S, Pirim I, Atasoy M, Ikbal M. HLA class I and class II genotyping in patients with chronic urticaria. Int Arch Allergy Immunol. 2008; 147:135–139.
80. Pacor ML, Di Lorenzo G, Mansueto P, Martinelli N, Esposito-Pellitteri M, Pradella P, Uxa L, Di Fede G, Rini G, Corrocher R. Relationship between human leucocyte antigen class I and class II and chronic idiopathic urticaria associated with aspirin and/or NSAIDs hypersensitivity. Mediators Inflamm. 2006; 2006:62489.
81. O'Donnell BF, O'Neill CM, Francis DM, Niimi N, Barr RM, Barlow RJ, Kobza Black A, Welsh KI, Greaves MW. Human leucocyte antigen class II associations in chronic idiopathic urticaria. Br J Dermatol. 1999; 140:853–858.
82. Oztas P, Onder M, Gonen S, Oztas MO, Soylemezoglu O. Is there any relationship between human leucocyte antigen class II and chronic urticaria? (chronic urticaria and HLA class II). Yonsei Med J. 2004; 45:392–395.
83. Chen J, Tan Z, Li J, Xiong P. Association of HLA-DRB1, DQB1 alleles with chronic urticaria. J Huazhong Univ Sci Technolog Med Sci. 2005; 25:354–356.
84. Kim SH, Choi JH, Lee KW, Kim SH, Shin ES, Oh HB, Suh CH, Nahm DH, Park HS. The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin Exp Allergy. 2005; 35:339–344.
85. Ye YM, Hur GY, Park HJ, Kim SH, Kim HM, Park HS. Association of specific IgE to staphylococcal superantigens with the phenotype of chronic urticaria. J Korean Med Sci. 2008; 23:845–851.
86. Ciotti M, Marrone A, Potter C, Owens IS. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics. 1997; 7:485–495.
87. Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JD. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res. 2001; 61:3566–3569.
88. Palikhe NS, Kim SH, Nam YH, Ye YM, Park HS. Polymorphisms of aspirin-metabolizing enzymes CYP2C9, NAT2 and UGT1A6 in aspirin-intolerant urticaria. Allergy Asthma Immunol Res. 2011; 3:273–276.
89. Petrov V, Fagard R, Lijnen P. Effect of protease inhibitors on angiotensin-converting enzyme activity in human T-lymphocytes. Am J Hypertens. 2000; 13:535–539.
90. Foreman JC, Jordan CC, Oehme P, Renner H. Structure-activity relationships for some substance P-related peptides that cause wheal and flare reactions in human skin. J Physiol. 1983; 335:449–465.
91. Piotrowski W, Foreman JC. On the actions of substance P, somatostatin, and vasoactive intestinal polypeptide on rat peritoneal mast cells and in human skin. Naunyn Schmiedebergs Arch Pharmacol. 1985; 331:364–368.
92. Bas M, Hoffmann TK, Tiemann B, Dao VT, Bantis C, Balz V, Schultz-Coulon HJ, Stark T, Schuler P, Greve J, Ivens K, Bier H, Kojda G. Potential genetic risk factors in angiotensin-converting enzyme-inhibitor-induced angio-oedema. Br J Clin Pharmacol. 2010; 69:179–186.
93. Gulec M, Caliskaner Z, Tunca Y, Ozturk S, Bozoglu E, Gul D, Erel F, Kartal O, Karaayvaz M. The role of ace gene polymorphism in the development of angioedema secondary to angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Allergol Immunopathol (Madr). 2008; 36:134–140.
94. Akcali C, Ozkur M, Erbagci Z, Benlier N, Aynacioglu AS. Association of insertion/deletion polymorphism of the angiotensin-converting enzyme gene with angio-oedema accompanying chronic urticaria but not chronic urticaria without angio-oedema or the autologous serum skin test response. J Eur Acad Dermatol Venereol. 2008; 22:83–86.
95. Rhee I, Veillette A. Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nat Immunol. 2012; 13:439–447.
96. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM, Conn MT, Chang M, Chang SY, Saiki RK, Catanese JJ, Leong DU, Garcia VE, McAllister LB, Jeffery DA, Lee AT, Batliwalla F, Remmers E, Criswell LA, Seldin MF, Kastner DL, Amos CI, Sninsky JJ, Gregersen PK. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet. 2004; 75:330–337.
97. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, MacMurray J, Meloni GF, Lucarelli P, Pellecchia M, Eisenbarth GS, Comings D, Mustelin T. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 2004; 36:337–338.
98. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE, Chang M, Ramos P, Baechler EC, Batliwalla FM, Novitzke J, Williams AH, Gillett C, Rodine P, Graham RR, Ardlie KG, Gaffney PM, Moser KL, Petri M, Begovich AB, Gregersen PK, Behrens TW. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet. 2004; 75:504–507.
99. Brzoza Z, Grzeszczak W, Rogala B, Trautsolt W, Moczulski D. PTPN22 polymorphism presumably plays a role in the genetic background of chronic spontaneous autoreactive urticaria. Dermatology. 2012; 224:340–345.
100. Brzoza Z, Grzeszczak W, Trautsolt W, Moczulski D. Protein tyrosine phosphatase-22 (PTPN-22) polymorphism in the pathogenesis of chronic urticaria. Allergy. 2011; 66:1392–1393.
Full Text Links
  • AAIR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr